医学
结肠镜检查
呕吐
内科学
胃肠病学
恶心
穿孔
PEG比率
比沙科迪
腹痛
安慰剂
外科
结直肠癌
材料科学
替代医学
冶金
经济
病理
冲孔
癌症
财务
作者
Neal Osborn,Howard Franklin,Prateek Sharma
标识
DOI:10.14309/00000434-201810001-00506
摘要
Introduction: NER1006, a 1 L polyethylene glycol (PEG) bowel prep with ascorbate, demonstrated non-inferiority in overall colon cleansing efficacy with numerically superior right colon cleansing vs oral sulfate (trisulfate), 2 L PEG with ascorbate (2 L PEG), and sodium picosulfate + magnesium salt solution (SP+MS) in three phase 3 trials. In this pooled analysis of these trials, the safety profile of NER1006 was evaluated. Methods: Data were pooled from 3 colonoscopist-blinded trials: NOCT (NER1006 vs trisulfate): p.m./ a.m. split dosing (2-day); MORA (NER1006 vs 2 L PEG): p.m./a.m. split or a.m.-only dosing (1-day); and DAYB (NER1006 vs SP+MS): day before-only dosing (1-day). Trials included adults aged 18-85 y scheduled for colonoscopy. Safety assessments included treatment-emergent AEs and clinical lab evaluations. Analysis included patients in any treatment arm for whom patient diary records could not rule out that they received study drug at least once. Results: Analysis included 1797 patients overall (NER1006 [n=1028]; mean age 55.8 y [range, 18-86 y]; 55.9% female). NER1006 was well tolerated; most AEs were related to the gastrointestinal (GI) system (Table). Discontinuations due to AE occurred in 2 (0.2%) patients in NER1006 1-day group (vomiting) and 1 (0.4%) patient each in trisulfate (abdominal pain) and 2 L PEG (nausea plus vomiting) groups. Four (0.4%) of 1028 patients each experienced 1 serious AE in NER1006 groups (2-day: alcohol abuse, ileus, and intestinal perforation during polypectomy; 1-day: ovarian abscess) and 1 (0.4%) occurred in trisulfate group (GI hemorrhage). No serious AEs were considered drug-related by the investigator. There were no clinically significant differences in hematology or clinical chemistry results between 2 NER1006 regimens or across treatment groups. There were 4 AEs of mild hypernatremia (2-day NER1006, n=3; 1-day a.m.-only NER1006, n=1) based on tests from day of colonoscopy; tests reverted to normal by 2±1 days after colonoscopy. Within 7±1 days after colonoscopy, 1.7% of 1028 patients in the NER1006 overall group with normal sodium levels at baseline had serum sodium levels above upper limit of normal (ie, >145 mmol/L); none of these 17 patients had an AE of hypernatremia. No medical intervention was required for any electrolyte shifts. Conclusion: Combined with the lower volume and favorable right-sided colon cleansing, the current safety findings support NER1006 as a bowel prep for colonoscopy in adults.506 Figure 1 No Caption available.
科研通智能强力驱动
Strongly Powered by AbleSci AI